Lisdexamfetamine

Drug Profile

Lisdexamfetamine

Alternative Names: Elvanse; Elvanse Adult; LDX; Lisdexamfetamine dimesilate; Lisdexamfetamine dimesylate; NRP-104; S-877489; SPD-489; Tyvense; Venvanse; Vyvanse

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator New River Pharmaceuticals
  • Developer Lindner Center of HOPE; Shionogi; Shire
  • Class Amides; Amphetamines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder; Eating disorders
  • Phase II Mood disorders
  • Discontinued Bipolar depression; Cocaine abuse; Major depressive disorder; Schizophrenia; Sleep disorders

Most Recent Events

  • 21 Feb 2017 Shire announces intention to submit NDA to the Japanese regulatory body for Attention-deficit hyperactivity disorder in 2017 (Shire pipeline, February 2017)
  • 16 Jan 2017 Shionogi completes an extension phase II trial in Attention-deficit hyperactivity disorder (In children, In adolescents) in Japan (JapicCTI-132128)
  • 28 Nov 2016 Launched for Eating disorders in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top